CDNA - CareDx, Inc

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
21.65
-0.64 (-2.87%)
At close: 4:00PM EST

21.65 0.00 (0.00%)
After hours: 4:15PM EST

Stock chart is not supported by your current browser
Previous Close22.29
Open22.19
Bid21.71 x 1100
Ask21.80 x 900
Day's Range21.30 - 22.23
52 Week Range18.75 - 41.27
Volume378,771
Avg. Volume767,366
Market Cap918.739M
Beta (5Y Monthly)0.81
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    CareDx Reports Preliminary Fourth Quarter and Full Year 2019 Results

    CareDx, Inc. (CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported preliminary financial results for the fourth quarter and full year ended December 31, 2019. Preliminary revenue for the three months ended December 31, 2019 is expected to be between $35.7 million and $36.0 million, an increase of 52% to 53% compared with $23.5 million in the fourth quarter of 2018. Product revenue in the three months ended December 31, 2019 is expected to be $5.1 million, compared to $4.6 million in the same period in 2018.

  • GlobeNewswire

    CareDx’s AlloSeq cfDNA Awarded CE Mark Approval

    SOUTH SAN FRANCISCO, Calif., Jan. 10, 2020 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of.

  • GlobeNewswire

    CareDx Leadership at ASTS Meeting

    SOUTH SAN FRANCISCO, Calif., Jan. 09, 2020 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of.

  • GlobeNewswire

    CareDx's False Advertising Complaint Upheld By Court

    SOUTH SAN FRANCISCO, Calif., Jan. 08, 2020 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of.

  • GlobeNewswire

    CareDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BRISBANE, Calif., Dec. 24, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically.

  • GlobeNewswire

    CareDx Supports Bipartisan Legislation to Protect Kidney Transplant Patients

    CareDx, Inc. (CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, applauds Congress on the introduction of bipartisan legislation in the House of Representatives that would extend Medicare coverage of immunosuppressive medications for kidney transplant recipients.

  • GlobeNewswire

    CareDx to Participate in Upcoming Investor Conferences

    BRISBANE, Calif., Nov. 19, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically.

  • GlobeNewswire

    CareDx at ASN Kidney Week

    BRISBANE, Calif., Nov. 06, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically.

  • GlobeNewswire

    CareDx Advances Patient Care with AlloSure 3.0

    CareDx, Inc. (CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announces the launch of AlloSure 3.0, the next iteration in continued transplant patient-focused improvements. CareDx continues to drive innovation in the field. CareDx has new data showing AlloSure provides more in-depth insights into patients with TCMR1A and borderline rejection.

  • GlobeNewswire

    CareDx Reports Third Quarter 2019 Results

    BRISBANE, Calif., Oct. 31, 2019 -- CareDx, Inc. (NASDAQ: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically.

  • GlobeNewswire

    CareDx to Announce Third Quarter 2019 Financial Results on October 31st, 2019

    BRISBANE, Calif., Oct. 17, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically.

  • GlobeNewswire

    CareDx Files Patent Infringement Lawsuit Against Eurofins Viracor

    CareDx, Inc. (CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that it has filed a patent infringement suit against Eurofins Viracor, Inc., in the United States District Court for Delaware.  CareDx is asserting U.S. Patent No. 8,703,652, which is exclusively licensed to CareDx from Stanford University.  This patent covers non-invasive monitoring of organ transplant rejection through cell-free DNA analysis. CareDx is seeking all available remedies, including damages and injunctive relief.

  • GlobeNewswire

    CareDx Adds HistoMap To Testing Portfolio

    CareDx, Inc. (CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced a strategic partnership with NanoString to develop HistoMap, a gene expression profiling (GEP) solution to identify allograft rejection in transplant biopsy tissue. Seattle-based NanoString (NSTG) is a leading provider of life science tools for translational research and molecular diagnostic products.

  • GlobeNewswire

    CareDx’s KidneyCare iBox Technology Clinically Validated in BMJ Publication

    BRISBANE, Calif., Sept. 23, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically.

  • GlobeNewswire

    CareDx Launches AlloSeq® Tx 17 at ASHI/BANFF Meeting

    BRISBANE, Calif., Sept. 20, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically.

  • GlobeNewswire

    First Patient Enrolled in Landmark CareDx OKRA Registry

    BRISBANE, Calif., Sept. 18, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically.

  • GlobeNewswire

    CareDx to Participate in the Cantor Fitzgerald Global Healthcare Conference

    BRISBANE, Calif., Sept. 17, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically.

  • GlobeNewswire

    CareDx launches AlloSeq® cfDNA at ESOT 2019

    BRISBANE, Calif., Sept. 12, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically.

  • GlobeNewswire

    CareDx Acquires XynManagement

    BRISBANE, Calif., Aug. 28, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically.

  • GlobeNewswire

    Chris Cournoyer Joins CareDx Board of Directors

    BRISBANE, Calif., Aug. 27, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically.

  • GlobeNewswire

    AlloSure for Heart Transplant Patients Receives CMS Draft Coverage

    BRISBANE, Calif., Aug. 22, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically.

  • GlobeNewswire

    Fear of Rejection is Transplant Patient’s Top Concern

    CareDx, Inc. (CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced results of a national informational survey conducted with The American Association of Kidney Patients (AAKP) of kidney transplant recipients that assessed their key concerns about monitoring kidney health post-transplant.

  • ACCESSWIRE

    CDNA INVESTIGATION ALERT: Bernstein Liebhard LLP Reminds Investors of Its Investigation of CareDx Inc.- CDNA

    NEW YORK, NY / ACCESSWIRE / August 9, 2019 / Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of CareDx ...

  • GlobeNewswire

    Bragar Eagel & Squire, P.C. is Investigating CareDx, Inc. (NASDAQ: CDNA) on Behalf of Stockholders and Encourages CareDx Investors to Contact the Firm

    NEW YORK, Aug. 05, 2019 -- Bragar Eagel & Squire, P.C. is investigating potential claims against CareDx, Inc. (NASDAQ: CDNA) on behalf of CareDx investors. Our.